Diagnosis and biomarkers of predementia in Alzheimer’s disease (2010)
- Authors:
- USP affiliated authors: FORLENZA, ORESTES VICENTE - FM ; GATTAZ, WAGNER FARID - FM
- Unidade: FM
- DOI: 10.1186/1741-7015-8-89
- Subjects: BIOMARCADORES; DEMÊNCIA (DIAGNÓSTICO); DOENÇA DE ALZHEIMER (DIAGNÓSTICO)
- Language: Inglês
- Imprenta:
- Source:
- Título: BMC Medicine
- ISSN: 1741-7015
- Volume/Número/Paginação/Ano: v. 8, n. 89, in press, 2010
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
FORLENZA, Orestes V. e DINIZ, Breno S. e GATTAZ, Wagner F. Diagnosis and biomarkers of predementia in Alzheimer’s disease. BMC Medicine, v. 8, n. 89, 2010Tradução . . Disponível em: https://doi.org/10.1186/1741-7015-8-89. Acesso em: 10 jan. 2026. -
APA
Forlenza, O. V., Diniz, B. S., & Gattaz, W. F. (2010). Diagnosis and biomarkers of predementia in Alzheimer’s disease. BMC Medicine, 8( 89). doi:10.1186/1741-7015-8-89 -
NLM
Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer’s disease [Internet]. BMC Medicine. 2010 ; 8( 89):[citado 2026 jan. 10 ] Available from: https://doi.org/10.1186/1741-7015-8-89 -
Vancouver
Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer’s disease [Internet]. BMC Medicine. 2010 ; 8( 89):[citado 2026 jan. 10 ] Available from: https://doi.org/10.1186/1741-7015-8-89 - Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial
- Single-nucleotide polymorphisms of GSK3B, GAB2 and SORL1 in late-onset Alzheimer's disease: interactions with the APOE genotype
- Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression
- Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease
- Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study
- Inhibition of phospolipase A2 modulates glycogen synthase activity and tau phosphorylation in primary cultures of cortical and hippocampal neurons
- Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer’s disease: a 4-year follow-up study
- Interleukin-1β Serum Levels is Increased in Antidepressant-Free Elderly Depressed Patients
- Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease
- Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study
Informações sobre o DOI: 10.1186/1741-7015-8-89 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
